Purple Biotech Partners with Mount Sinai to Advance Cancer Immunotherapy

Purple Biotech ( (PPBT) ) has provided an announcement.

Purple Biotech announced on February 3, 2025, its collaboration with the Icahn School of Medicine at Mount Sinai to explore the immunoregulation of NK and T cells within the tumor microenvironment using its CAPTN-3 tri-specific antibody platform. This partnership aims to deepen the understanding of CAPTN-3’s mechanisms and could enhance tumor-specific immunity against multiple cancer types, potentially leading to improved responses in resistant cancer patients. This collaboration reflects the growing interest in multi-specific engagers and positions Purple Biotech to advance CAPTN-3 towards human clinical studies, which may pave the way for effective treatments for challenging tumor indications.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies that address tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, with CM24 and NT219 having shown promising results in early clinical studies. Based in Rehovot, Israel, Purple Biotech is advancing its CAPTN-3 platform, which engages both T cells and NK cells to enhance immune responses within the tumor microenvironment.

YTD Price Performance: -29.19%

Average Trading Volume: 969,185

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $8.88M

Find detailed analytics on PPBT stock on TipRanks’ Stock Analysis page.